In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-<i>a</i>]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice

In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-<i>a</i>]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice

Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-co...

Full description

Bibliographic Details
Main Authors: Zahid Rafiq Bhat, Manvendra Kumar, Nisha Sharma, Umesh Prasad Yadav, Tashvinder Singh, Gaurav Joshi, Brahmam Pujala, Mohd Raja, Joydeep Chatterjee, Kulbhushan Tikoo, Sandeep Singh, Raj Kumar
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Molecules
Subjects:
EGFR inhibitor
lung cancer
xenograft mice model
imidazo[1,2-<i>a</i>]quinoxaline
in vivo
microsomal stability
Online Access:https://www.mdpi.com/1420-3049/27/17/5540

Internet

https://www.mdpi.com/1420-3049/27/17/5540

Similar Items